[stock_market_widget type="clock-markets" template="analog" timezone="America/New_York" title="New York" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Europe/London" title="London" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Europe/Brussels" title="Brussels" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Asia/Hong_Kong" title="Hong Kong" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Asia/Tokyo" title="Tokyo" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Australia/Sydney" title="Sydney" style="font-size: 7px; width: 100px;"]

Stock Market News

Becton Dickinson settles charges over infusion pump risks, SEC says

12/16/2024

Less than a minute

2024.12.16 17:01

© Reuters. FILE PHOTO: The seal of the U.S. Securities and Exchange Commission is seen at their headquarters in Washington, D.C., U.S., May 12, 2021. Picture taken May 12, 2021. REUTERS/Andrew Kelly/File Photo

WASHINGTON (Reuters) – The U.S. Securities and Exchange Commission said on Monday that it had settled charges with Becton Dickinson (NYSE:) and Co. over allegations it misled investors about risks associated with its Alaris infusion pump.

The SEC said Becton Dickinson agreed to pay a $175 million civil penalty to settle the charges, which also allege that the company overstated its income by failing to disclose the costs of software repairs associated with the pump.

Source link

12/16/2024

Less than a minute